Keros Therapeutics, Inc. Common Stock (KROS) is a publicly traded Healthcare sector company. As of September 8, 2026, KROS trades at $11.59 with a market cap of $224.44M and a P/E ratio of 4.81. KROS moved -1.50% today. Year to date, KROS is -45.14%; over the trailing twelve months it is -27.80%. Its 52-week range spans $9.12 to $22.55. Analyst consensus is buy with an average price target of $18.80. Rallies surfaces KROS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies community data for KROS shows anonymized retail investor ownership, positioning, sentiment, and portfolio context when enough community data is available.
| Metric | Value |
|---|---|
| Price | $11.59 |
| Market Cap | $224.44M |
| P/E Ratio | 4.81 |
| EPS | $2.34 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.55 |
| 52-Week Low | $9.12 |
| Volume | 56.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $243.86M |
| Net Income | $87.01M |
| Gross Margin | 0.00% |
6 analysts cover KROS: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.80.